![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in DAA failure patients: an integrative analysis
|
|
|
EASL 2023 June 23 Vienna
Christiana Graf1,2, Roberta D'Ambrosio3, Elisabetta Degasperi3, Stefania Paolucci4, Jordi Llaneras5, Johannes Vermehren1, Georg Dultz1, Kai-Henrik Peiffer1, Eva Herrmann6, Stefan Zeuzem1,7, Maria Buti5, Pietro Lampertico3,8, Julia Dietz1,7 Christoph Sarrazin1,7,9
![0701231](../images/070123/060123-1/0701231.gif)
"we retreat SOF/Vel/Vox failures with G/P+SOF, and 2 patients in the study who were decompensated with Child Pugh cirrhosis they were retreated with G/P+Sof." Graf
![0701232](../images/070123/060123-1/0701232.gif)
![0701233](../images/070123/060123-1/0701233.gif)
![0701234](../images/070123/060123-1/0701234.gif)
![0701235](../images/070123/060123-1/0701235.gif)
![0701236](../images/070123/060123-1/0701236.gif)
![0701237](../images/070123/060123-1/0701237.gif)
![0701238](../images/070123/060123-1/0701238.gif)
![0701239](../images/070123/060123-1/0701239.gif)
![07012310](../images/070123/060123-1/07012310.gif)
![07012311](../images/070123/060123-1/07012311.gif)
![07012312](../images/070123/060123-1/07012312.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|